Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04846634 Not yet recruiting - Clinical trials for Resectable Locally Advanced Non-small Cell Lung Cancer

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

ALTER-L043
Start date: August 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open label, phase II study.

NCT ID: NCT04840758 Not yet recruiting - Clinical trials for Multiple Primary Lung Cancer

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Start date: June 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)

NCT ID: NCT04836728 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer Metastatic

Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

CCICC-002b
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This prospective,multicenter, open-labe phase II study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of IV non-small cell lung cancer.

NCT ID: NCT04814056 Not yet recruiting - Clinical trials for NRG1-fused Non-small Cell Lung Cancer

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

This is an open-label, sing-arm, phase IV clinical study. The study is designed to evaluate the efficacy of Afatinib in treatment of NRG1-fused locally advanced/metastatic non-small cell lung cancer (NSCLC), and explore the clinical factors that may predict the effectiveness of treatment.

NCT ID: NCT04790539 Not yet recruiting - Clinical trials for Extensive Stage Small Cell Lung Cancer

a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This project is to to explore the safety and efficacy of shr-1210 combined with albumin, paclitaxel and carboplatin in the first-line treatment of extensive small cell lung cancer

NCT ID: NCT04782089 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Start date: May 6, 2021
Phase: N/A
Study type: Interventional

This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment

NCT ID: NCT04772287 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, controlled, double-blind, single-center Phase III clinical study in patients with EGFR/ALK mutation negative stage II-IIIB (N2) non-small cell lung cancer (NSCLC) after complete tumor resection. To evaluate the effectiveness and safety of toripalimab compared with placebo combined with platinum-containing dual-drug chemotherapy.

NCT ID: NCT04755738 Not yet recruiting - Clinical trials for Advanced Non Small Cell Lung Cancer

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

MWA
Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial.

NCT ID: NCT04753918 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study

Start date: March 2021
Phase: Early Phase 1
Study type: Interventional

This research study is being conducted to assess the safety and feasibility of using a newly developed bronchoscopic light delivery method of photodynamic therapy to treat subjects with solid tumors in peripheral lung, who are inoperable or refused surgery.

NCT ID: NCT04749407 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer Stage III

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

Start date: February 2021
Phase:
Study type: Observational

This study aims to dynamically monitor the expression profile status of peripheral blood mononuclear cells (PBMC) and the changes in circulating tumor DNA (ctDNA) levels in patients with stage III locally advanced unresectable non-small-cell lung cancer(NSCLC) after concurrent chemoradiotherapy or sequential chemoradiotherapy, and to explore biomarkers related to the immune microenvironment and the optimal time point for immunotherapy after chemoradiotherapy.